The Avita Medical Inc (ASX: AVH) share price is pushing higher again on Friday, extending its strong short-term rebound.
In afternoon trade, the Avita share price has shot up 8.33% to $1.30, taking its 1 week gain to almost 20%.
That surge is standing out against a weaker backdrop, with the S&P/ASX All Ordinaries Index (ASX: XAO) down 0.3% to 9,138 points. This comes as investors react to the latest developments in the Middle East between the US, Israel and Iran.
Fortunately for Avita, the rebound has been building for several sessions this week. The stock rose 6.31% on Wednesday and added another 1.69% on Thursday, despite widespread selling across the ASX.
Let’s take a look at what’s driving the shares higher.
Major US government deal supports sentiment
Avita’s update this week appears to be the key catalyst, centred on a 10-year agreement with the US Biomedical Advanced Research and Development Authority (BARDA).
Worth up to US$25.5 million, the deal is aimed at strengthening US emergency preparedness for large-scale burn casualty events.
BARDA will have access to 3,000 units of Avita’s RECELL treatment platform at any point during the contract period. Avita will also manage inventory, logistics support, and deployment readiness.
The full contract value includes procurement options that may not all be exercised. Avita said about US$3.97 million is expected to flow through as revenue over the 10-year term via annual access and readiness support fees.
The market is repricing execution risk
Friday’s rally is also notable because it comes after a prolonged period of heavy selling in the stock.
Even with this week’s rebound, Avita shares remain down more than 50% over the past 12 months. This shows how aggressively the market had already marked down execution risk and earnings uncertainty.
Foolish takeaway
Avita’s sharp rebound this week shows how quickly sentiment can turn when a beaten-down small-cap healthcare stock lands a credible long-term government contract.
The BARDA update clearly improves revenue visibility and gives the market a stronger reason to revisit the recovery outlook.
That said, it is still a small-cap healthcare stock with elevated execution risk, and this week’s rally does not change the fact that the shares remain down over the past year.
Personally, this is not the type of stock I would be chasing after a sharp short-term move. I would rather put my money into larger, more established businesses with steadier earnings and less share price volatility.
The post Why this ASX healthcare stock is surging while the market sinks on Middle East fears appeared first on The Motley Fool Australia.
Should you invest $1,000 in Avita Medical right now?
Before you buy Avita Medical shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Avita Medical wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Broker sees 26% upside in ASX healthcare share behind Chemist Warehouse
- Why Beetaloo, Fortescue, Orora, and Whitehaven Coal shares are dropping today
- This ASX critical minerals company could more than double in value: Broker
- Could this ASX-listed gold mine developer really increase six-fold?
- 3 BetaShares ETFs I think can beat the market over 5 years
Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Avita Medical. The Motley Fool Australia has recommended Avita Medical. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.